Your browser is no longer supported. Please, upgrade your browser.
Settings
FSTX [NASD]
F-star Therapeutics, Inc.
Index- P/E- EPS (ttm)-8.18 Insider Own0.30% Shs Outstand17.02M Perf Week7.34%
Market Cap144.41M Forward P/E- EPS next Y-2.63 Insider Trans-1.74% Shs Float12.48M Perf Month-10.89%
Income-36.40M PEG- EPS next Q-0.58 Inst Own64.60% Short Float1.40% Perf Quarter29.62%
Sales14.20M P/S10.17 EPS this Y-65.50% Inst Trans- Short Ratio0.87 Perf Half Y-27.68%
Book/sh5.82 P/B1.18 EPS next Y14.10% ROA-54.10% Target Price31.17 Perf Year54.73%
Cash/sh- P/C- EPS next 5Y- ROE-74.60% 52W Range3.88 - 15.50 Perf YTD-30.40%
Dividend- P/FCF- EPS past 5Y-8.20% ROI-52.10% 52W High-55.68% Beta1.77
Dividend %- Quick Ratio8.60 Sales past 5Y64.10% Gross Margin- 52W Low76.88% ATR0.53
Employees75 Current Ratio8.60 Sales Q/Q115.30% Oper. Margin- RSI (14)48.32 Volatility7.26% 7.09%
OptionableYes Debt/Eq0.00 EPS Q/Q40.10% Profit Margin- Rel Volume0.86 Prev Close6.94
ShortableNo LT Debt/Eq0.10 EarningsAug 12 BMO Payout- Avg Volume201.81K Price6.87
Recom1.40 SMA20-0.91% SMA50-3.37% SMA200-16.14% Volume173,956 Change-1.01%
Oct-20-21 08:00AM  
Sep-16-21 08:00AM  
Sep-09-21 09:00AM  
Aug-12-21 08:00AM  
Aug-10-21 08:00AM  
Aug-04-21 08:00AM  
Aug-02-21 10:10AM  
Jul-26-21 08:00AM  
Jul-09-21 08:00AM  
Jul-08-21 08:00AM  
May-17-21 08:00AM  
07:15AM  
May-10-21 08:00AM  
May-07-21 07:00AM  
May-06-21 04:50PM  
Apr-19-21 09:27AM  
Apr-16-21 11:39AM  
Apr-10-21 09:22AM  
Apr-01-21 08:00AM  
Mar-29-21 08:00AM  
07:15AM  
Mar-17-21 03:44AM  
Mar-16-21 08:00AM  
Mar-04-21 08:00AM  
Jan-20-21 08:00AM  
Jan-06-21 08:00AM  
Jan-04-21 08:00AM  
Dec-03-20 08:00AM  
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kayitalire LouisChief Medical OfficerOct 04Sale7.236446254,319Oct 06 04:38 PM
Kayitalire LouisChief Medical OfficerJul 02Sale8.431,0548,88554,383Jul 07 09:13 PM